OBJECTIVE: To determine the long-term results of liver transplantation for well- or moderately differentiated hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: HCC patient selection for liver transplantation remains controversial, and deciding exclusively on the strength of criteria such as number and size of nodules appears prognostically inaccurate. METHODS: Since 1991, preoperative tumor grading has been used at our center to establish whether a patient with HCC is fit for transplantation. Poorly differentiated HCC cases were excluded, while size and number of nodules were not considered as absolute selection criteria. Thirty-three patients with moderately or well-differentiated HCC were prospectively studied after liver transplantation. A group of 15 patients with incidental HCC transplanted during the same period were also evaluated and compared with the 33 patients with preoperatively diagnosed HCC. RESULTS: On histologic examination, 38% of the entire group of 48 patients did not meet the "Milan criteria" and 42% were pTNM stages III and IV. The median follow-up was 44 months. The 5-year actuarial survival rate was 75% and recurrence-free survival was 92%. HCC recurred in only 3 patients (6%). The only histomorphologic variable differing significantly between incidental and nonincidental HCC was nodule size. The timing of diagnosis (incidental vs. nonincidental HCC), the Milan criteria, and the TNM stage revealed no statistically significant impact on overall and recurrence-free survival rates. CONCLUSIONS: The routine pre-orthotopic liver transplantation tumor grading may represent a valid tool in the selection of unresectable HCC patients for transplantation.
OBJECTIVE: To determine the long-term results of liver transplantation for well- or moderately differentiated hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: HCC patient selection for liver transplantation remains controversial, and deciding exclusively on the strength of criteria such as number and size of nodules appears prognostically inaccurate. METHODS: Since 1991, preoperative tumor grading has been used at our center to establish whether a patient with HCC is fit for transplantation. Poorly differentiated HCC cases were excluded, while size and number of nodules were not considered as absolute selection criteria. Thirty-three patients with moderately or well-differentiated HCC were prospectively studied after liver transplantation. A group of 15 patients with incidental HCC transplanted during the same period were also evaluated and compared with the 33 patients with preoperatively diagnosed HCC. RESULTS: On histologic examination, 38% of the entire group of 48 patients did not meet the "Milan criteria" and 42% were pTNM stages III and IV. The median follow-up was 44 months. The 5-year actuarial survival rate was 75% and recurrence-free survival was 92%. HCC recurred in only 3 patients (6%). The only histomorphologic variable differing significantly between incidental and nonincidental HCC was nodule size. The timing of diagnosis (incidental vs. nonincidental HCC), the Milan criteria, and the TNM stage revealed no statistically significant impact on overall and recurrence-free survival rates. CONCLUSIONS: The routine pre-orthotopic liver transplantation tumor grading may represent a valid tool in the selection of unresectable HCC patients for transplantation.
Authors: H J Schlitt; M Neipp; A Weimann; K J Oldhafer; E Schmoll; K Boeker; B Nashan; S Kubicka; H Maschek; G Tusch; R Raab; B Ringe; M P Manns; R Pichlmayr Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: J W Marsh; I Dvorchik; M Subotin; V Balan; J Rakela; E P Popechitelev; V Subbotin; A Casavilla; B I Carr; J J Fung; S Iwatsuki Journal: Hepatology Date: 1997-08 Impact factor: 17.425
Authors: Y Ito; N Matsuura; M Sakon; E Miyoshi; K Noda; T Takeda; K Umeshita; H Nagano; S Nakamori; K Dono; M Tsujimoto; M Nakahara; K Nakao; N Taniguchi; M Monden Journal: Hepatology Date: 1999-07 Impact factor: 17.425
Authors: J M Llovet; J Bruix; J Fuster; A Castells; J C Garcia-Valdecasas; L Grande; A Franca; C Brú; M Navasa; M C Ayuso; M Solé; M I Real; R Vilana; A Rimola; J Visa; J Rodés Journal: Hepatology Date: 1998-06 Impact factor: 17.425
Authors: Y Sasaki; S Imaoka; S Ishiguro; H Nakano; H Kasugai; M Fujita; E Inoue; O Ishikawa; H Furukawa; S Nakamori; C Kuroda; T Iwanaga Journal: Surgery Date: 1996-03 Impact factor: 3.982
Authors: Umberto Cillo; Alessandro Vitale; Filippo Navaglia; Daniela Basso; Umberto Montin; Marco Bassanello; Francesco D'Amico; Francesco Antonio Ciarleglio; Alberto Brolese; Giacomo Zanus; Vito De Pascale; Mario Plebani; Davide Francesco D'Amico Journal: World J Gastroenterol Date: 2005-11-28 Impact factor: 5.742
Authors: C Angonese; A Baldan; U Cillo; A D'Alessandro; M De Antoni; M De Giorgio; A Masotto; D Marino; M Massani; M Mazzucco; E Miola; D Neri; D Paccagnella; G Pivetta; L Tommasi; F Tremolada; A Tufano; G Zanus; F Farinati Journal: Gut Date: 2006-03 Impact factor: 23.059
Authors: John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Zhen-Yu Xiao; Babak Banan; Jianluo Jia; Pamela T Manning; Ronald R Hiebsch; Muthukumar Gunasekaran; Gundumi A Upadhya; William A Frazier; Thalachallour Mohanakumar; Yiing Lin; William C Chapman Journal: Liver Transpl Date: 2015-01-29 Impact factor: 5.799
Authors: Richard S Young; Mohammed Aldiwani; Abdul R Hakeem; Amit Nair; Ashley Guthrie; Judy Wyatt; Darren Treanor; Gareth Morris-Stiff; Rebecca L Jones; K Rajendra Prasad Journal: HPB (Oxford) Date: 2012-12-27 Impact factor: 3.647